61results about How to "Good tumor treatment" patented technology

The invention provides an FPGA (field programmable gate array) control-based all-solid-state high-voltage nanosecond pulse generator, and belongs to the field of bio-electromagnetic technology. The nanosecond pulse generator mainly comprises a power supply system, a pulse forming system, a pulse measurement system, an FPGA control system, a signal conversion system and a portable computer. In the generator, the output pulse amplitude is between 0 and 10kV, the pulse width is between 200 and 1000ns, the pulse frequency is between 1 and 1000Hz, the falling edge is between 30 and 40ns, the number of pulse is between 1 and 1000, and particular parameters are determined according the requirement of tumor treatment. The FPGA control-based all-solid-state high-voltage nanosecond pulse generator has the characteristics of intelligent regulation of pulse parameters (pulse amplitude, width, frequency and number), optical fiber transmission, high parameter accuracy, long service life, small size, low failure rate, good security and the like; and the generator outputs high pulse frequency, and is advantageous to quick searching of the optimal window parameters for inducing tumor cell apoptosis by virtue of intelligent regulation, so that the tumor treatment effect is improved. The FPGA control-based all-solid-state high-voltage nanosecond pulse generator can be widely applied to tumor treatment.

The invention relates to a portable high-voltage nanosecond squarer which belongs to a medicinal device for inducing cancer cell apoptosis by using a high-voltage nanosecond square wave pulse electric field. The portable high-voltage nanosecond squarer mainly comprises a power supply system, a high-voltage direct current module, a low-voltage power supply, a pulse forming system and a pulse shaping and counting system. The portable high-voltage nanosecond squarer has output pulses with highest amplitude of 15kV, pulse width adjustment range of 50ns-1us, rising edge gradient of reaching 10ns and controllable recurrence frequency of 0.2-15Hz; and the quantity of the output pulses of the portable high-voltage nanosecond squarer can be set. The portable high-voltage nanosecond squarer can be adjusted in multiple-parameters (pulse amplitude, pulse width, recurrence frequency, pulse quantity and the like), large-range and flexible and independent way, and is beneficial to researching the optimal window parameter of the cancer cell apoptosis and promoting the cancer cell apoptosis as well as improving the cancer treatment effect. Meanwhile, the portable high-voltage nanosecond squarer has compact and light structure, reliable work, simple operation and convenient popularization and application, and can be widely applied to the treatment of various cancers.

The invention provides a composite gold nanorod carrier having photo-thermal / photodynamic therapy treatment performance and a preparation method thereof. The composite gold nanorod carrier uses a gold nanorod as a core and uses silicon dioxide as a shell layer, a near infrared fluorescent dye for photodynamic therapy is modified on the outer surface of the shell layer. The preparation method comprises the steps that a chloroauric acid solution and a cetyl trimethyl ammonium bromide solution are mixed, a sodium borohydride ice water mixed solution is added to obtain a nano gold seed solution A; a silver nitrate solution and a chloroauric acid solution are added to a binary surface active agent solution, a hydrochloric acid is added after reaction to obtain a solution B, then ascorbic acid and the solution A are added, and a gold nanorod is obtained after reaction; a tetraethoxysilane methanol solution and an aminopropyl trimethoxy silane methanol solution are added to a gold nanorod solution to obtain composite nanoparticles; 1-(3-dimethyl amino propyl)-3-ethyl carbodiimide hydrochloride is added to the near infrared fluorescent dye, then N-hydroxyl succinimide is added to obtain a solution C; the composite nanoparticle solution is mixed with the solution C to obtain a product.

The invention discloses a carrier-free co-assembled tumor targeting anti-cancer nano medicine as well as a preparation method and application thereof. The carrier-free dual anti-cancer nano medicine is prepared from a hydrophobic medicine, namely ursolic acid, together with board-spectrum anti-tumor medicines such as doxorubicin in water through co-assembling, in addition, a fluorescence labeling nucleic acid aptamer, a molecular target, an antibody or polypeptide and the like with tumor targeting functions are adsorbed to the surface of the medicine through mutual electrostatic functions, then the carrier-free co-assembled tumor targeting anti-cancer nano medicine with tumor targeting and tumor microenvironment response is prepared, a synergic anti-tumor function is achieved, diagnosis and treatment integration is achieved, particularly the medicine has outstanding functions in preventing tumor transfer, and more importantly the problems that a conventional nano carrier is complex in system, indefinite in in-vivo metabolism and the like are solved.

The invention provides a bismuth selenide nanocomposite material and a preparation method and application thereof. The bismuth selenide nanocomposite material comprises polyvinylpyrrolidone, selenocysteine, and bismuth selenide coated by the polyvinylpyrrolidone and the selenocysteine. The bismuth selenide nanocomposite material has a good light-heat conversion function, can achieve effective combination of thermotherapy and radiotherapy to play a synergistic effect, and can overcome respective defects of the two therapy methods to obtain the optimal tumor treatment effect; after completion of the radiotherapy, the selenocysteine is degraded from the surface of the material and can effectively enter a living body to participate in synthesis of selenium protein, so that the body immunity is enhanced, and the side effects caused by the radiotherapy are reduced.

The present invention relates to the field of targeting drug delivery and particularly relates to a tumor targeting drug and a preparation method thereof. The tumor targeting drug comprises a targeting carrier and an anti-tumor drug loaded on the carrier. The targeting carrier comprises hepatitis B virus-like particles a RGD sequence recombinant protein. The tumor targeting drug can be obtained bya genetic engineering method and operation is simple. The tumor targeting drug has good targeting, high bioavailability and small side effects.

The invention relates to a macrophage-mediated drug-loaded hyaluronic acid nanohydrogel and preparation thereof. A drug-loaded hyaluronic acid nanohydrogel is obtained by synthesizing polypyrrole in situ from the interior of a hyaluronic acid nanohydrogel, and loading a drug; and the macrophage-covered drug-loaded nanohydrogel is obtained by performing co-incubation on the drug-loaded hyaluronic acid nanohydrogel and mouse macrophages. The macrophage-mediated drug-loaded nanohydrogel prepared by the method has the advantages of low toxicity, safety, avoidance of phagocytosis of a reticuloendothelial system, and specific targeting in tumor areas when used for delivery of anti-cancer drugs, and has potential application prospects in tumor treatment.

The invention belongs to the field of biological treatment of tumors and relates to an immune cell culture method capable of simultaneously activating CD4 <+>and CD8<+>T cells. The immune cell culture method comprises the steps of placing single nuclear cells which are well separated in a culture solution containing rhIL-12 and IL-4 ligands and an IL-10 ligand, culturing for 8-12h, then adding levamisole, continuously culturing for 8-12h, adding Anti-CD3McAb and rhIL-2, continuously culturing for 2-3 days, and then alternately adding into the culture medium containing the rhIL-2 and the culture medium containing the Anti-CD3McAb and the rhIL-2, wherein the intermediate culture time is 2-3 days. The scheme for preparing a cell factor compound is as follows: collecting cell supernatant liquid within 3-14 days after the beginning of culture, performing low-temperature ultracentrifugation, performing ultrafiltration by an ultrafiltration centrifugal tube, and performing microfiltration by a microprous filtration membrane, wherein filtrate is a natural cell factor mixture. By adopting the culture method provided by the invention, sustained proliferation of cells can be kept for 30 days. NCM contains a variety of cell factors and can stimulate immune cells of a human body to play autoimmune anti-tumor activity.

The invention discloses a CIK cell with high cytotoxic activity and its application in tumor cell immunotherapy. The CIK cell is prepared by the following steps: (1) taking the peripheral blood of a patient, and collecting the peripheral blood mononuclear cell part; The peripheral blood mononuclear cells collected in step (1) were partially centrifuged, and the supernatant was discarded to obtain mononuclear cells; 6 / mL cells, add the complete medium containing 500~2000IU / mL gamma interferon and 80~120ng / mL compound (I), and start the induction culture; the complete medium includes RPMI 1640 cell culture medium containing 10% FBS by volume percentage; (4) After 20-28 hours of cell culture in step (3), add 50-1000ng / mL anti-human CD3 monoclonal antibody and 500-2000IU / mL recombinant human IL-2, and continue to induce culture, every 2-3 days The CIK cells were subcultured once, and the induced culture time was 13-21 days to obtain CIK cells. The CIK cells can be used for tumor cell immunotherapy.

The invention relates to the field of camptothecine drugs, in particular to a 10-HCPT (10-hydroxycamptothecine) derivative, a synthesis method and an application thereof. The 10-HCPT derivative is a derivative which is formed by esterifying a hydroxyl radical at site 10 in 10-HCPT and has an ester structure. The molecular polarity of the derivative is greatly reduced, the biological membrane crossing speed is remarkably increased, the speed and the number of drugs entering tumor cells are increased, the utilization of the drugs is increased, the better anti-tumor effect can be realized, and the toxic and side effects are reduced.

The invention relates to a portable high-voltage nanosecond squarer which belongs to a medicinal device for inducing cancer cell apoptosis by using a high-voltage nanosecond square wave pulse electric field. The portable high-voltage nanosecond squarer mainly comprises a power supply system, a high-voltage direct current module, a low-voltage power supply, a pulse forming system and a pulse shaping and counting system. The portable high-voltage nanosecond squarer has output pulses with highest amplitude of 15kV, pulse width adjustment range of 50ns-1us, rising edge gradient of reaching 10ns and controllable recurrence frequency of 0.2-15Hz; and the quantity of the output pulses of the portable high-voltage nanosecond squarer can be set. The portable high-voltage nanosecond squarer can be adjusted in multiple-parameters (pulse amplitude, pulse width, recurrence frequency, pulse quantity and the like), large-range and flexible and independent way, and is beneficial to researching the optimal window parameter of the cancer cell apoptosis and promoting the cancer cell apoptosis as well as improving the cancer treatment effect. Meanwhile, the portable high-voltage nanosecond squarer has compact and light structure, reliable work, simple operation and convenient popularization and application, and can be widely applied to the treatment of various cancers.

The present invention relates to a docetaxel nanometer lipid injection. The invention also relates to a method for preparing the docetaxel nanometer lipid injection. The invention further relates to the application of the docetaxel nanometer lipid injection for preparing medicament for treating a tumor. The nanometer preparation of the invention is capable of prolonging the medicament action time, conveying the medicament with a target, reducing the administration dose under the precondition of ensuring the medicament action, alleviating or avoiding medicament toxin and side effects, improving the medicament action stability, and being benefited for the medicament storage, thus it is capable of implementing the development of the medicament which has advantages in the aspects of a high yield, automatization, large scale, low cost, convenient carry and storage, small dose and low side-effect.

The invention discloses CIK cells with high cytotoxic activity for immune treatment of tumor cells. The CIK cells are prepared through the following steps that firstly, peripheral blood of a patient is sampled, and the peripheral blood mononuclear cell part is collected; secondly, the peripheral blood mononuclear cell part collected in the first step is centrifuged, supernate is discarded, and mononuclear cells are obtained; thirdly, the mononuclear cells are taken according to 1*106 / mL, and a complete medium including 500-2,000 IU / mL of gamma interferon and 80-120 ng / mL of a compound is added, and induction culturing is started, wherein the complete medium includes RPMI 1640 cell culture fluid with 10% of FBS by the volume percent; fourthly, after the cells in the third step are cultured for 20-28 hours, 50-1,000 ng / mL anti-human CD3 monoclonal antibodies and 500-2,000 IU / mL of recombination human IL-2 are added, induction culturing is continued, subculture is conducted once every other two to three days, the induction culturing time is 13 to 21 days, and the CIK cells are obtained. The CIK cells can be used for immune treatment of the tumor cells.

The invention provides a pulsed magnet field generator based on coil spherical focusing and IGBT single transistor parallel connection. The pulsed magnet field generator comprises a power supply system, a pulse current forming system, five coil spherical optimization focusing devices, a signal transformation system and a synchronized trigger module, and the switching power supply of the power supply system carry out voltage reduction on an alternating current power supply to form direct currents, is connected with the pulse current forming system, the signal transformation system and the synchronized trigger module and supplies power. The output ends of pulse generating modules M1-M5are connected with current carrying coils C1-C5 in the five coil spherical optimization focusing devices respectively. The electrical-optical converter J2 of the signal transformation system is respectively connected with the control ends of the pulse generating modules M1-M5. The output end of the synchronized trigger module is respectively connected with the electrical-optical converter J1 and the electrical-optical converter J2 of the signal transformation system. The pulsed magnet field generator is high in integration level, longer in service life and higher in work efficiency, the circuit size is greatly reduced, and the loss of the whole circuit is lowered.

The invention provides a recombinant human serum albumin-collagen binding domain fusion protein of a tumor specific targeting matrix and application, and relates to the technical field of biological medicines. According to the invention, gene fusion is formed by utilizing HSA and CBD in different molecular structure forms, expression can be obtained in a constructed recombinant engineering host, and the recombinant fusion protein meeting medicinal requirements is obtained through large-scale fermentation preparation. The recombinant fusion protein has solid tumor specific targeting, can be used as a broad-spectrum matrix carrier starting material, and can be coupled with any tumor treatment drugs, small molecular compounds or cytotoxic proteins to form an innovative drug compound. The recombinant fusion protein drug compound also has long-acting property, can prolong the half-life period of a coupling drug in vivo, and has a clinical curative effect obviously superior to that of a monomeric drug in tumor resistance. The invention also provides an application of the drug compound in preparation of drugs for solid tumor specific targeted therapy and preparation of corresponding drugs.

The invention relates to a bionic nano-carrier for reducing excessive calcium ions in tumors and a preparation method and application thereof. The preparation method comprises the steps that a mixed solution of triethylamine and monobrominated polyethylene glycol is added into a gold nanoparticle solution modified with a calcium ion trapping agent, a reaction is conducted for 1-3 days under stirring, dialysis is conducted, and a bionic nanoparticle solution with the calcium ion trapping agent protected by polyethylene glycol is obtained; a mixed solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N-hydroxysuccinimide and a tumor targeting agent is added into the bionic nanoparticle solution with the calcium ion trapping agent protected by polyethylene glycol, a reaction is conducted for 1-3 days under stirring, dialysis is conducted, and the calcium-ion-trapped bionic nanoparticle solution with a tumor targeting function is obtained. The prepared bionic nano particles are good in biocompatibility, safe, non-toxic, excellent in stability and suitable for the medical field; and the choices of the calcium ion trapping agent and the tumor targeting agent used herein are wide-ranging, and the modification method is simple.

The invention provides a cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes and a preparation method of the cervical cancer therapeutic vaccine, and relates tothe field of genetic engineering. The attenuated Listeria monocytogenes Lemo-C07 are taken as a background, and a virulence factor LLO protein of the strain carries two key mutant amino acid sites, sothat the virulence of the strain is greatly reduced, but part of the proliferation ability in the cells is still retained. According to the vaccine, on the basis of the attenuated Listeria monocytogenes, a molecular biological technique is utilized to integrate a full-length gene of a specific antigen E7 of the cervical cancer to the downstream part of an LLO gene of the Listeria monocytogenes, thereby constructing and obtaining the recombinant attenuated Listeria monocytogenes containing the tumor specific antigen E7. The vaccine has the capabilities of presenting the specific antigen and activating the anti-tumor cellular immunity of the body, and has the remarkable tumor treatment effect.

The invention relates to the technical field of medical equipment, in particular to a tumor radiotherapy device capable of realizing accurate positioning. The tumor radiotherapy device capable of realizing the accurate positioning comprises a base, a rotary barrel, a second driving mechanism and a reset mechanism, wherein two connecting elements are hinged to the side wall of the rotary barrel andare independently provided with a radiation light source and a positioning light source; the radiation light source and the positioning light source are distributed at an interval on one circle around the axial line of the rotary barrel; a minimum radius angle of the centers of the positioning light source and the radiation light source on the circle is a; the second driving mechanism is used fordriving the two connecting elements to move to enable the positioning light source and the radiation light source to synchronously swing at equal amplitude; and the reset mechanism is used for controlling the first driving mechanism to enable the rotary barrel to rotate along a first direction at a set angle a so as to move the radiation light source to the position of the positioning light source before resetting. The tumor radiotherapy device capable of realizing the accurate positioning can be used for reducing a deviation between a practical radiation area of the radiation light source and a simulated positioning area of the positioning light source

The invention relates to the technical field of medical equipment and in particular relates to a tumor radiotherapy machine which comprises a base, a rotating cylinder, a second driving mechanism anda return mechanism, wherein connecting parts are hinged with the side wall of the rotating cylinder; the number of the connecting parts is two; the two connecting parts are respectively provided witha radiation light source and a positioning light source and are distributed at an interval on a circle along the axis of the rotating cylinder; the minimum central angle of centers of the positioninglight source and the radiation light source on the circle is a; the second driving mechanism is used for driving the two connecting parts to move and used for enabling the radiation light source and the positioning light source to swing synchronously with an equal amplitude; and the return mechanism is used for controlling the first driving mechanism and used for enabling the rotating cylinder torotate for a set angle a along a first direction so as to move the radiation light source to a position of the positioning light source before return. By adopting the tumor radiotherapy machine provided by the invention, the deviation of an actual radiation area of the radiation light source and a simulated positioning area of the positioning light source can be reduced.

The invention discloses an EGFR (epidermal growth factor receptor) inhibitor and medical application thereof. The compound is a compound as shown in a formula I, pharmaceutically acceptable salt or prodrug. The compound can be applied to preparation of medicines for treating and / or preventing cancer.

The invention discloses a CIK cell with high cytotoxic activity for tumor cell immunotherapy. The CIK cell is prepared by the following steps: (1) taking peripheral blood from a patient, and collecting the peripheral blood mononuclear cell part; The collected peripheral blood mononuclear cells were partially centrifuged, and the supernatant was discarded to obtain mononuclear cells; 6 / mL cells, add the complete medium containing 500~2000IU / mL gamma interferon and 80~120ng / mL compound (I), and start the induction culture; the complete medium includes RPMI 1640 cell culture medium containing 10% FBS by volume percentage; (4) After cell culture in step (3) for 20-28 hours, add 50-1000ng / mL anti-human CD3 monoclonal antibody and 500-2000IU / mL recombinant human IL-2, continue to induce culture, every 2-3 days The CIK cells were subcultured once, and the induced culture time was 13-21 days to obtain CIK cells. The CIK cells can be used for tumor cell immunotherapy.

The invention belongs to the field of biotechnology, and relates to an ROS-sensitive tumor-targeted gene delivery system and a preparation method thereof. According to the system, an ROS-sensitive micromolecular crosslinking agent is used for crosslinking low-molecular-weight polyethyleneimine to form an ROS-sensitive cationic polymer, an SP polypeptide is modified to serve as a targeted functional group, nanoparticles are targeted into a breast cancer tumor site after mediating and gene compounding, the crosslinked polymer is responsively dissociated into small molecules under a high-level ROS atmosphere in a tumor cell, load-releasing genes take effects, and finally, effective gene delivery is realized. A new gene delivery platform is provided, the gene transfection effect is good, and the growth of tumors can be effectively inhibited through delivery of therapeutic genes siPlk1.

The invention discloses novel iridium complexes as well as a preparation method and application thereof. The iridium complexes are formed by combining electron-deficient naphthoquinoline or pyrazine serving as an N^N ligand with a large conjugated C^N ligand with an electron donating property. The iridium complexes with rich excited states can be subjected to energy transfer with oxygen under the illumination condition to generate rich singlet oxygen, and under the hypoxic condition, the iridium complexes can generate active oxygen species such as hydroxyl free radicals due to relatively strong electron transfer, so that the iridium complexes have a good photodynamic effect; besides, the N^N ligand with electron-deficient property and the C^N ligand with electron-donating property respectively regulate HOMO and LUMO energy levels, so that the iridium complexes emit red light and have a better application prospect in the field of biological imaging materials.

The invention provides an FPGA (field programmable gate array) control-based all-solid-state high-voltage nanosecond pulse generator, and belongs to the field of bio-electromagnetic technology. The nanosecond pulse generator mainly comprises a power supply system, a pulse forming system, a pulse measurement system, an FPGA control system, a signal conversion system and a portable computer. In the generator, the output pulse amplitude is between 0 and 10kV, the pulse width is between 200 and 1000ns, the pulse frequency is between 1 and 1000Hz, the falling edge is between 30 and 40ns, the number of pulse is between 1 and 1000, and particular parameters are determined according the requirement of tumor treatment. The FPGA control-based all-solid-state high-voltage nanosecond pulse generator has the characteristics of intelligent regulation of pulse parameters (pulse amplitude, width, frequency and number), optical fiber transmission, high parameter accuracy, long service life, small size, low failure rate, good security and the like; and the generator outputs high pulse frequency, and is advantageous to quick searching of the optimal window parameters for inducing tumor cell apoptosis by virtue of intelligent regulation, so that the tumor treatment effect is improved. The FPGA control-based all-solid-state high-voltage nanosecond pulse generator can be widely applied to tumor treatment.

The invention belongs to the field of nano drug delivery systems, and discloses a platinum-icodextrin-polycaprolactone macromolecular compound, a nano drug delivery system and application of the nano drug delivery system. The compound is a polycaprolactone modified icodextrin-platinum conjugate, the icodextrin-platinum conjugate is formed by connecting a carboxylated tetravalent platinum compound to icodextrin through an ester bond, and the polycaprolactone is coupled with the icodextrin through the ester bond; the molecular weight of the polycaprolactone is 1 kDa to 10 kDa, and the molecular weight of the icodextrin is 10 kDa to 20 kDa; the grafting rate of the polycaprolactone on the icodextrin is 0.5-1, and the mass percentage of a platinum element in the macromolecular compound is 1%-5%. The compound contains a hydrophilic fragment icodextrin, a hydrophobic fragment polycaprolactone and tetravalent platinum, as a tumor treatment drug, the toxic and side effects of cis-platinum are reduced, the stability of circulation in blood is improved, so that the bioavailability of platinum is improved, and the anti-tumor effect is greatly enhanced.

The invention relates to the technical field of medical equipment, in particular to medical equipment for radiation therapy. The medical equipment for radiation therapy comprises a base, a rotary drum, a second driving mechanism and a reset mechanism. Two connecting pieces are hinged to the side wall of the rotary drum, a radioactive light source and a positioning light source are mounted on the two connecting pieces respectively and distributed on a circle around the axis of the rotary drum at intervals, and the minimum central angle of the center of the positioning light source and the center of the radioactive light source on the circle is a; the second driving mechanism is used for driving the two connecting pieces to move, so that the radioactive light source and the positioning lightsource synchronously swing at equal amplitude; the reset mechanism is used for controlling the first driving mechanism to enable the rotary drum to rotate by a set angle a in the first direction so as to move the radioactive light source to the position of the positioning light source before resetting. According to the medical equipment for radiation therapy, the deviation between the actual radiation area of the radioactive light source and the simulated positioning area of the positioning light source can be reduced.

The invention discloses a quinazoline derivative serving as an EGFR inhibitor and application of the derivative. The quinazoline derivative is a compound shown in formula I and is pharmaceutically acceptable salts or prodrugs. The compound can be used for being prepared into drugs for treating and / or preventing cancers, wherein the formula I is shown in the description.

The invention relates to the field of camptothecine drugs, in particular to a 10-HCPT (10-hydroxycamptothecine) derivative, a synthesis method and an application thereof. The 10-HCPT derivative is a derivative which is formed by esterifying a hydroxyl radical at site 10 in 10-HCPT and has an ester structure. The molecular polarity of the derivative is greatly reduced, the biological membrane crossing speed is remarkably increased, the speed and the number of drugs entering tumor cells are increased, the utilization of the drugs is increased, the better anti-tumor effect can be realized, and the toxic and side effects are reduced.

The invention discloses a CDK4-FLT3 inhibitor and an application of the CDK4-FLT3 inhibitor. The compound is a compound shown as a formula I, and pharmaceutically acceptable salt, hydrate, solvate, metabolite, stereoisomer, tautomer or prodrug thereof. The compound can be used for preparing medicines for treating and / or preventing cancers.